Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ
Closed
Aug 24, 2026
Day's Range
78.0152 wk Range
32.89Overview - KNSA - Kiniksa Pharmaceuticals International, plc
Key Statistics
Valuation
Enterprise Value
5.64B
P/E (Trailing)
‪79.82‬
P/E (Forward)
‪48.85‬
PEG Ratio
‪2.12‬
Price / Sales (TTM)
‪7.33‬
Price / Book
‪9.42‬
EV / EBITDA
‪55.36‬
Profitability
Gross Margin
‪54.17%‬
Profit Margin
‪9.59%‬
Operating Margin
‪11.16%‬
Return on Assets
‪8.04%‬
Return on Equity
‪14.03%‬
Ownership
Shares Outstanding
77.97M
Float
40.19M
Short % of Shares Outstanding
‪10.80%‬
Held by Insiders
‪3.48%‬
Held by Institutions
‪100.79%‬
Price stats
Beta
‪0.08‬
50-Day Avg
‪67.03‬
200-Day Avg
‪50.91‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
8 analysts
Average price target
‪$ 98.00‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - KNSA - Kiniksa Pharmaceuticals International, plc
Peers - KNSA - Kiniksa Pharmaceuticals International, plc
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- KNKNSANASDAQKiniksa Pharmaceuticals International, plc6.16BMarket Cap+58.19%52-week change79.83P/E (Trailing)‪9.59%‬Profit Margin
- NBIXNASDAQNeurocrine Biosciences Inc.15.50BMarket Cap+12.18%52-week change22.34P/E (Trailing)‪20.91%‬Profit Margin
- ALALKSNASDAQAlkermes plc8.10BMarket Cap+40.00%52-week change127.37P/E (Trailing)‪3.96%‬Profit Margin
- LNTHNASDAQLantheus Holdings, Inc.6.52BMarket Cap+43.82%52-week change23.92P/E (Trailing)‪17.69%‬Profit Margin
- AMRXNASDAQAmneal Pharmaceuticals Inc.6.23BMarket Cap+48.19%52-week change37.60P/E (Trailing)‪5.04%‬Profit Margin
- ALMNASDAQAlmonty Industries Inc.5.33BMarket Cap+76.82%52-week change84.14P/E (Trailing)‪125.23%‬Profit Margin
- AMLXNASDAQAmylyx Pharmaceuticals, Inc. Common Stock4.41BMarket Cap+76.55%52-week change2.54P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - KNSA - Kiniksa Pharmaceuticals International, plc
About
Kiniksa Pharmaceuticals International, plc is a global biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies for patients with serious unmet medical needs, particularly in cardiovascular and inflammatory diseases. Its lead product, ARCALYST (rilonacept), is an…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
